Wiener Medizinische Wochenschrift

, Volume 163, Issue 15–16, pp 347–353

Advanced basal cell carcinoma

main topic


Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure is the best known exogenous factor in BCC development. This is also the target for primary prevention. Advanced BCC include locally advanced tumors and metastatic tumors. Prognosis is worse compared to stage I and II BCCs. Mohs or micrographically controlled surgery is the gold standard of treatment. In patients with tumors that cannot be completely removed radiotherapy was the only alternative in the past. More recently new drugs for targeted therapy of signaling pathways like sonic hedgehog or epidermal growth factor receptor became available. More small molecules are under investigation. Since the complete response rates are limited, future research has to evaluate their combination with surgery.


Basal cell carcinoma Ultraviolet-light exposure Sonic hedgehog Epidermal growth factor Surgery 

Das fortgeschrittene Basalzellkarzinom


Das Basalzellkarzinom (BCC) ist weltweit der häufigste maligne Tumor. Die Exposition gegenüber ultravioletter Strahlung gilt als bekanntester exogener Faktor in der BCC-Entwicklung. Hierauf zielen auch alle primären Präventionsmaßnahmen. Unter dem Begriff der fortgeschrittenen BCC werden lokal ausgedehnte Tumore und metastasierende Tumore zusammengefaßt. Ihre Prognose ist deutlich schlechter als bei den Stadien I und II. Mohs- oder mikrographisch-kontrollierte Chirurgie gilt als Goldstandard in der Behandlung. Bei Patienten, wo eine komplette Exzision des Tumors unmöglich war, blieb in der Vergangenheit nur die Strahlentherapie als Alternative. In jüngerer Zeit gibt es Medikamente für eine zielgerichtete Behandlung mit Beeinflussung von Signalkaskaden wie Sonic hedgehog oder epidermalem Wachstumsfaktor-Rezeptor. Weitere kleine Moleküle werden geprüft. Da bislang die kompletten Remissionsraten unter dieser Therapie limitiert sind, gilt es ihre bestmögliche Kombination mit der Chirurgie zu bestimmen.


Basalzellkarzinom Ultraviolett-Exposition Sonic hedgehog Epidermaler Wachstumsfaktor Chirurgie 


  1. 1.
    Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Fartasch M, Diepgen TL, Schmitt J, Drexsler H. The relationship between occupational sun exposure and nonmelanoma skin cancer. Dtsch Ärztebl Int. 2012;109:715–20.PubMedGoogle Scholar
  3. 3.
    Wollina U. Nonmelanoma skin cancer on the rise. J Cutan Aesthet Surg. 2012;5:11.PubMedGoogle Scholar
  4. 4.
    Chinem VP, Mior HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86:292–305.PubMedCrossRefGoogle Scholar
  5. 5.
    Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. Indian J Dermatol. 2011;56:670–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang JM, Gao XM. Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients. Chin Med J (Engl). 2013;126:211–4.PubMedGoogle Scholar
  7. 7.
    Moser S, Borm J, Michic-Probst D, Jacobsen C, Kruse-Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. doi:pii:S2212-4403(12)00398-7.Google Scholar
  8. 8.
    Greinert R, Boniol M. Skin cancer—primary and secondary prevention (information campaigns and screening)—with a focus on children & sunbeds. Progr Biophys Mol Biol. 2011;107:473–6.CrossRefGoogle Scholar
  9. 9.
    Wollina U. Addiction to tanning—a new cause of early onset of nonmelanoma skin cancer. Open Dermatol J. 2009;3:144–9.CrossRefGoogle Scholar
  10. 10.
    Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258.PubMedGoogle Scholar
  11. 11.
    Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol 2011;165:30–4.PubMedCrossRefGoogle Scholar
  12. 12.
    de Vries E, Arnold M, Altsitsiadis E, Trakatelli M, Hinrichs B, Stockfleth E, et al. Potential impact of interventions resulting in reduced exposure to ultraviolet (UV) radiation (UVA and UVB) on skin cancer incidence in four European countries, 2010–2050. Br J Dermatol. 2012;167(Suppl 2):53–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Burnett ME, Wang SQ. Current sunscreen controversies: a critical review. Photodermatol Photoimmunol Photomed. 2011;27:58–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Lien MH, Fenske NA, Glass LF. Advances in the chemoprevention of nonmelanoma skin cancer in high-risk organ transplant recipients. Semin Oncol. 2012;39:134–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102:1835–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma—molecular biology and potential new therapies. J Clin Invest. 2012;122:455–63.PubMedCrossRefGoogle Scholar
  18. 18.
    Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, et al. Hair cycle dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+mice exposed to radiation. Cancer Res. 2006;66:6606–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67:531–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2012;2:CD007041.PubMedGoogle Scholar
  22. 22.
    Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119:1994–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Skiveren J, Mikkelsen MR, Daugberg H, Wulf HC. Skin reactions and quality of life after X-ray therapy of basal cell carcinoma. J Skin Cancer. 2012:825095.Google Scholar
  24. 24.
    Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep. 2011;3:e 57.CrossRefGoogle Scholar
  25. 25.
    Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, Chimenti S. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, nonsuperficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol. 2011;21:952–8.PubMedGoogle Scholar
  27. 27.
    Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel nonsurgical treatment for basal cell carcinomas: response and follow up 12–21 months after treatment. Lasers Surg Med. 2011;43:72–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Lawrence CM, Haniffa M, Dahl MG. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: five-year follow-up data. Br J Dermatol. 2009;160:573–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs ‘micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with five-years’ follow-up. Lancet Oncol. 2008;9:1149–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal cell carcinoma of the face: randomized controlled trial. Lancet. 2004;364:1766–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Daudén E; BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol. 2011;25:1304–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47.PubMedCrossRefGoogle Scholar
  33. 33.
    Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol. 2004;50:722–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol. 2002;12:558–61.PubMedGoogle Scholar
  37. 37.
    Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40:153–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Souza CS, Felicio LB, Ferreira J, Kurachi C, Bentley MV, Tedesco AC, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for nonmelanoma skin cancer. Photodiagnosis Photodyn Ther. 2009;6:207–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012;18:I5–9.CrossRefGoogle Scholar
  40. 40.
    Varga E, Korom I, Raskó E, Kis E, Varga J, Oláh J, et al. Neglected basal cell carcinomas in the twenty first century. J Skin Cancer. 2011;2011:392151.PubMedGoogle Scholar
  41. 41.
    Wollina U, Pabst F, Krönert C, Schorcht J, Haroske G, Klemm E, et al. High-risk basal cell carcinoma: an update. Expert Rev Dermatol. 2010;5:357–68.CrossRefGoogle Scholar
  42. 42.
    Wollina U, Helm C, Schreiber A, Brandl H-G. Extensive cranial infiltration by basal cell carcinoma. J Cutan Med Surg. 2006;10:257–8.PubMedGoogle Scholar
  43. 43.
    Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al. Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res. 2009;29:2655–63.PubMedGoogle Scholar
  44. 44.
    Wollina U, Bayyoud Y, Krönert C, Nowak A. Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center. J Cutan Aesthet Surg. 2012;5:12–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW. Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg. 2007;58:250–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol. 2009;60:1045–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6.PubMedGoogle Scholar
  49. 49.
    Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262.PubMedCrossRefGoogle Scholar
  50. 50.
    Mevio N, Bertino G, Occhini A, Scelsi D, Tagliabue M, Mura F, Benazzo M. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori. 2012;98:308–13.PubMedGoogle Scholar
  51. 51.
    Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005;131:300–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Wollina U. Cetuximab in nonmelanoma skin cancer. Expert Opin Biol Ther. 2012;12:949–56.PubMedCrossRefGoogle Scholar
  53. 53.
    Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61.PubMedCrossRefGoogle Scholar
  54. 54.
    Caron J, Dereure O, Kerob D, Lebbe C, Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Müller H, Eisendle K, Gastl G, Höpfl R, Zelger B. Palliative therapy of giant basal cell carcinoma with the monoclonal antiepidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361:1164–72.PubMedCrossRefGoogle Scholar
  57. 57.
    LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11.PubMedCrossRefGoogle Scholar
  58. 58.
    Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med. 2012;366:2717–9.CrossRefGoogle Scholar
  60. 60.
    Fellner C. Vismodegib (Erivedge) for advanced basal cell carcinoma. PT. 2012;37(12):670–82.Google Scholar
  61. 61.
    Stanton BZ, Peng LF. Small molecule modulators of the sonic hedgehog signaling pathway. Mol Biosyst. 2010;6:44–54.PubMedCrossRefGoogle Scholar
  62. 62.
    Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011;30(Suppl 4):14–8.CrossRefGoogle Scholar
  63. 63.
    Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34.PubMedCrossRefGoogle Scholar
  64. 64.
    Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330:22–32.PubMedCrossRefGoogle Scholar
  65. 65.
    Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI mediated transcription and tumor cell growth by small molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60.PubMedCrossRefGoogle Scholar
  66. 66.
    Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther. 2012;11:165–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Department of Dermatology and AllergologyAcademic Teaching Hospital Dresden-FriedrichstadtDresdenGermany
  2. 2.Policlinic for Dermatology and VenereologyUniversity Hospital Lozenetz, Academic Educational Hospital of the Saint Kliment Ohridski UniversitySofiaBulgaria

Personalised recommendations